Cytidine Triphosphate Synthetase Inhibitor

2020 ◽  
Author(s):  
Keyword(s):  
Synthetase Inhibitor ◽  
Cytidine Triphosphate Synthetase

Inhibition of Platelet Aggregation by Human Placenta

1985 ◽  
Vol 54 (02) ◽  
pp. 431-437 ◽  
Author(s):  
M J Dembélé-Duchesne ◽  
A Laghchim Lahlou ◽  
H Thaler-Dao ◽  
A Crastes de Paulet
Keyword(s):  
Fatty Acid ◽  
Platelet Aggregation ◽  
Human Placenta ◽  
Cyclooxygenase Inhibitor ◽  
Synthetase Inhibitor ◽  
Inhibition Of Platelet Aggregation ◽  
Thromboxane Synthetase ◽  
Rabbit Platelets ◽  
High Doses ◽  
Induced Aggregation

SummaryHuman placental cytosol inhibits platelet aggregation induced by high doses of collagen. The aim of this study was to investigate whether this anti-aggregating activity was caused only by the presence of various activities already described in the placenta (an ADP-consuming enzyme, a fatty acid cyclooxygenase inhibitor, and a thromboxane synthetase inhibitor) or whether another factor was present.Heating the cytosol at 50° C for 6 min destroyed the inhibitor of collagen-induced aggregation. ADPase and the AA pathway inhibitors were not modified by this treatment. We therefore show the presence of an additional anti-aggregating factor: it is destroyed by heating at 50° C.We also tested for the presence of an inhibitor of AA release in the placental cytosol using three different methods (rabbit platelets in PRP, washed rabbit platelets, and NRK fibroblasts) but no inhibition could be evidenced.We conclude that this new anti-aggregating factor, which is probably a protein, acts neither through AA release inhibition nor AA cascade inhibition.

Platelet changes after a saturated fat meal and their prevention by dazmegrel, a thromboxane synthetase inhibitor

Lipids ◽  
1987 ◽  
Vol 22 (3) ◽  
pp. 159-162 ◽  
Author(s):  
J. J. F. Belch ◽  
A. R. Saniabadi ◽  
K. McLaughlin ◽  
C. D. Forbes
Keyword(s):  
Saturated Fat ◽  
Synthetase Inhibitor ◽  
Thromboxane Synthetase Inhibitor ◽  
Thromboxane Synthetase ◽  
Fat Meal

Prevention of cerebral vasospasm after SAH with a thromboxane synthetase inhibitor, OKY-1581

1982 ◽  
Vol 57 (1) ◽  
pp. 74-82 ◽  
Author(s):  
Tomio Sasaki ◽  
Susumu Wakai ◽  
Takao Asano ◽  
Kintomo Takakura ◽  
Keiji Sano
Keyword(s):  
Cerebral Vasospasm ◽  
Morphological Changes ◽  
Content Type ◽  
Synthetase Inhibitor ◽  
Thromboxane Synthetase Inhibitor ◽  
Thromboxane Synthetase ◽  
Basilar Arteries ◽  
Blood Injection ◽  
Subarachnoid Blood ◽  
Fine Print

✓ The efficacy of thromboxane synthetase inhibitor in the prevention of cerebral vasospasm after subarachnoid hemorrhage (SAH) was evaluated in a prolonged experiment using dogs. Changes in the diameter of the basilar artery were followed by angiography, and morphological changes were studied by photomicroscopy and electron microscopy. As a thromboxane synthetase inhibitor, OKY-1581 (sodium-(E)-3-(4(-3-pyridylmethyl)phenyl)-2-methylacrylate)was used. Dogs received intravenous injections of 160 mg of OKY-1581 dissolved in 2 ml of physiological saline immediately after subarachnoid blood injection. Subsequently, the animals received continuous intravenous infusion of the drug at the rate of 4 gm/50 ml/24 hours until sacrifice 4 days after induction of SAH. Control dogs received subarachnoid blood injection without treatment with OKY-1581. Angiographic examination revealed that the late spasm was almost completely abolished by the treatment with OKY-1581. Early spasm was also prevented, but the drug's effect was less prominent than it was on the late spasm. Morphological study revealed degenerative changes in the endothelium and myonecrotic changes in the tunica media following SAH in the basilar arteries of the treated as well as the untreated dogs. However, corrugation of the internal elastic lamina was almost completely absent in the treated dogs. The above results indicate that a disproportionate synthesis of thromboxane A2 plays an important role in the evolution of chronic cerebral vasospasm following SAH, and that drugs such as OKY-1581 that selectively inhibit thromboxane synthetase might be useful in the prevention of vasospasm.

2.P.40 Discovery of the squalene synthetase inhibitor CP-340,868

1997 ◽  
Vol 134 (1-2) ◽  
pp. 125 ◽  
Author(s):  
C.M. Hayward ◽  
E.S. Hamanaka ◽  
R.J. Aiello ◽  
H.J. Harwood ◽  
C.E. Aldinger ◽  
...  
Keyword(s):  
Synthetase Inhibitor ◽  
Squalene Synthetase

scholarly journals Effect of OKY-046, a thromboxane A2 synthetase inhibitor, on arachidonate-induced platelet aggregation : Possible role of "prostaglandin H2 steal" mechanism.

1986 ◽  
Vol 50 (11) ◽  
pp. 1071-1078 ◽  
Author(s):  
Tsunehiko KUZUYA ◽  
Masaharu OHMORI ◽  
Shiro HOSHIDA ◽  
Masakazu YAMAGISHI ◽  
Michitoshi INOUE ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Thromboxane A2 ◽  
Synthetase Inhibitor ◽  
Thromboxane A2 Synthetase Inhibitor

Attenuation of noradrenergic neurotransmission by the thromboxane synthetase inhibitor, UK 38,485

Life Sciences ◽  
1984 ◽  
Vol 35 (2) ◽  
pp. 221-228 ◽  
Author(s):  
Edwin K. Jackson ◽  
Howard D. Uderman ◽  
William A. Herzer ◽  
Robert A. Branch
Keyword(s):  
Synthetase Inhibitor ◽  
Thromboxane Synthetase Inhibitor ◽  
Thromboxane Synthetase
Sign in / Sign up

Export Citation Format

Share Document